Novartis Oncology Pipeline Has Three Potential Blockbusters In The Offing
Executive Summary
Novartis is aiming to launch a trio of potential blockbuster oncology drugs in the next few years that the firm hopes will erase the memory of several recent high-profile setbacks in multiple therapeutic areas
You may also be interested in...
Novartis’ Tasigna Joins Bristol’s Sprycel For CML Resistant To Gleevec
Novartis expects Tasigna (nilotinib) will be used in the small number of chronic myeloid leukemia patients with advanced resistant disease who already have received high dose Gleevec (imatinib), and as a result, is pricing the product on par with the 800 mg dose of Gleevec typically used for such patients - about $5,700 per month
Novartis’ Tasigna Joins Bristol’s Sprycel For CML Resistant To Gleevec
Novartis expects Tasigna (nilotinib) will be used in the small number of chronic myeloid leukemia patients with advanced resistant disease who already have received high dose Gleevec (imatinib), and as a result, is pricing the product on par with the 800 mg dose of Gleevec typically used for such patients - about $5,700 per month
Prexige “not approvable”
Novartis receives a "not approvable" letter from FDA for its COX-2 inhibitor lumiracoxib for osteoarthritic pain, firm announces Sept. 27. The negative outcome is not unexpected as CEO Daniel Vasella previously told analysts, "I don't think we will get an approval" (1"The Pink Sheet" Sept. 17, 2007, p. 11). Novartis is not completely abandoning hope that Prexige could be approved for specific populations, such as patients with a higher incidence of gastrointestinal complications, including those suffering from ulcers or being treated with anticoagulants...